The FDA’s decision marks J&J's Spravato as the first monotherapy for adults with treatment-resistant depression.

The U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Johnson & Johnson’s ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products. Below is a review of novel drug and biological products approved by the Food and Drug ...

The dawn of 2025 marks a turning point for the packaging industry in the UK, with the introduction of the Extended Producer Responsibility (EPR) regulations. / Credit: cybrain via GettyImages As we ...